Literature DB >> 16602813

Pharmacologic treatment of acute and chronic stress following trauma: 2006.

Jonathan R T Davidson1.   

Abstract

This article reviews pharmacologic treatment options for posttraumatic stress disorder (PTSD), focusing on goals of pharmacotherapy and the clinical trial evidence for drug treatments available for PTSD. The selective serotonin reuptake inhibitors (SSRIs) are recommended as first-line therapy for PTSD; the roles of these and other drug classes including anticonvulsants, mood enhancers, atypical antipsychotic agents, benzodiazepines, alpha1-adrenergic antagonists, and beta-blockers in achieving improvement in PTSD symptom and outcome scores, achieving remission, and avoiding relapse are discussed. Treatment of PTSD in association with other comorbid conditions is addressed, and the role of pharmacotherapy in treating early PTSD and acute stress disorder is examined. Dosing strategies for the SSRIs sertraline and paroxetine are provided, and an algorithm for PTSD pharmacotherapy is discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16602813

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  17 in total

1.  Varying uses of anticonvulsant medications.

Authors:  Elisa Cascade; Amir H Kalali; Richard H Weisler
Journal:  Psychiatry (Edgmont)       Date:  2008-06

Review 2.  [Psychosomatics and psychotraumatology of refugees and migrants : A Challenge for the Internist].

Authors:  J Schellong; F Epple; K Weidner
Journal:  Internist (Berl)       Date:  2016-05       Impact factor: 0.743

3.  Decreased suicidal ideation in depressed patients with or without comorbid posttraumatic stress disorder treated with selective serotonin reuptake inhibitors: an open study.

Authors:  Leo Sher; Barbara H Stanley; Kelly Posner; Mikkel Arendt; Michael F Grunebaum; Yuval Neria; Joseph John Mann; Maria A Oquendo
Journal:  Psychiatry Res       Date:  2012-03-06       Impact factor: 3.222

4.  A psychosomatic perspective on takotsubo cardiomyopathy: a case report.

Authors:  George Costin; Vaskar Mukerji; David Scott Resch
Journal:  Prim Care Companion CNS Disord       Date:  2011

Review 5.  Modulation of fear and anxiety by the endogenous cannabinoid system.

Authors:  Jasmeer P Chhatwal; Kerry J Ressler
Journal:  CNS Spectr       Date:  2007-03       Impact factor: 3.790

6.  Effects of systemic glutamatergic manipulations on conditioned eyeblink responses and hyperarousal in a rabbit model of post-traumatic stress disorder.

Authors:  Lauren B Burhans; Carrie A Smith-Bell; Bernard G Schreurs
Journal:  Behav Pharmacol       Date:  2017-10       Impact factor: 2.293

7.  Overlapping expression of serotonin transporters and neurokinin-1 receptors in posttraumatic stress disorder: a multi-tracer PET study.

Authors:  A Frick; F Åhs; Å M Palmquist; A Pissiota; U Wallenquist; M Fernandez; M Jonasson; L Appel; Ö Frans; M Lubberink; T Furmark; L von Knorring; M Fredrikson
Journal:  Mol Psychiatry       Date:  2015-12-01       Impact factor: 15.992

Review 8.  Recent progress in understanding the pathophysiology of post-traumatic stress disorder: implications for targeted pharmacological treatment.

Authors:  Christopher R Bailey; Elisabeth Cordell; Sean M Sobin; Alexander Neumeister
Journal:  CNS Drugs       Date:  2013-03       Impact factor: 5.749

9.  Endocannabinoid Modulation of Predator Stress-Induced Long-Term Anxiety in Rats.

Authors:  James Lim; Miki Igarashi; Kwang-Mook Jung; Stefania Butini; Giuseppe Campiani; Daniele Piomelli
Journal:  Neuropsychopharmacology       Date:  2015-09-11       Impact factor: 7.853

10.  Subacute fluoxetine enhances conditioned responding and conditioning-specific reflex modification of the rabbit nictitating membrane response: implications for drug treatment with selective serotonin reuptake inhibitors.

Authors:  Lauren B Burhans; Carrie A Smith-Bell; Bernard G Schreurs
Journal:  Behav Pharmacol       Date:  2013-02       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.